SOURCE: Cannabis Therapy Corp.

Cannabis Therapy Corp.

November 07, 2014 09:00 ET

Cannabis Therapy Corp. to Present at SeeThruEquity MicroCap Investor Forum November 12th in NYC

BOULDER, CO--(Marketwired - Nov 7, 2014) - Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"), a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, cannabinoid-based medicinal therapies and supplements (Nutraceuticals), today announced that Company CEO Dr. Soren Mogelsvang PhD and CFO Mr. Arnold Tinter will be presenting at SeeThruEquity's upcoming fall 2014 Microcap Investor Conference, being held at New York City's Convene Midtown East on November 12, 2014 at 10:00 A.M. Eastern.

Cannabis Therapy Corp. will present an overview of company's growth strategy alongside a snapshot of activities to-date, near term and long term goals, and the perceived roadmap for success in the rapidly growing hemp-based supplement sector. The Company offers a unique perspective with an extensive background in the biomedical industry and brings substantive insights as one of the only active national online retail marketers currently enjoying success in the sector.

The event runs from 8:00 am to 6:00pm at 730 3rd Avenue (between 45th St and 46th St.) and Cannabis Therapy Corp is scheduled to present at 10:00 A.M. in the Bryant Park Hub. The Company and organizers recommend early arrival as this is sure to be a popular and well attended event.

Members of the investment community interested in meeting with the Company's management during the conference can contact a representative at SeeThruEquity and can register to attend for the conference at the following link: http://goo.gl/z29yJS

For more information about Cannabis Therapy Corp. please visit www.cannabistherapy.com.

About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The Company's research is not paid for and is unbiased as it does not conduct any investment banking or commission based business. SeeThruEquity's research is contributed to by Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distributed to its opt-in investors along with Thomson Estimates, the leading estimates platform on Wall Street. SeeThruEquity Conferences are held approximately every quarter throughout the year and host industry professionals and investors who are looking for new ideas, opportunities, and corporate relationships. For more information, visit www.seethruequity.com.

About Cannabis Therapy Corp. (OTCQB: CTCO)
Cannabis Therapy Corp. aims to develop and market safe, phytocannabinoid-based medicinal products and to apply rigorous manufacturing and quality control standards to become a global leader in the research, development, manufacturing, testing and marketing of cannabinoid ingredients and therapies for both humans and animals. For more information visit www.cannabistherapy.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.

ON BEHALF OF THE BOARD,
Soren Mogelsvang, President & CEO
Cannabis Therapy Corp.

Contact Information